Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys

Journal of Toxicological Sciences

Volumn 32, Issue 4, 2007, Pages 411-420

  Kim, Choong Yong ^a   Kim, JeeEun ^a   Han, KangHyun ^a   Kim, SangKyoon ^b   Park, Kuilea ^b   Byun, Youngro ^c  

^a Korea Institute of Toxicology   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Cynomolgus monkeys; Oral heparin derivative; Toxicity screening

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEOXYCHOLIC ACID; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHEMICAL ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; ERYTHROCYTE COUNT; FOOD INTAKE; HEMATOLOGICAL PARAMETERS; LEUKOCYTE COUNT; MALE; MONKEY; NONHUMAN; SCREENING TEST; THROMBOCYTE COUNT; TOXICOLOGICAL PARAMETERS; UREA NITROGEN BLOOD LEVEL;

MACACA FASCICULARIS; MOROCCAN PEPPER VIRUS;

EID: 35649003327     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.32.411     Document Type: Article

References (32)

1. Aken, H.V., Bode, C.B., Darius, H., Diehm, C., Encke, A., Gulba, D.C., Haas, S., Haccke, W., Puhl, W., Quante, M., Riess, H., Scharf, R., Schellong, S., Schror, K., Schulte, K.-L. and Tebbe, U. (2001): Anticoagulation: The present and future. Clin. Appl. Thrombo. Hemost., 7, 195-204.
2. Alpert, J.S. and Dalen, J.E. (1994): Epidemiology and natural history of venous thromboembolism. Prog. Cardiovasc. Dis., 36, 417-422.
3. Baughman, R.A., Kapoor, S.C., Agarwal, R.K., Kisicki, J., Catella-Lawson, F. and FitzGerald, G.A. (1998): Oral delivery of anticoagulant doses of heparin; A randomized, double-blind, controlled study in humans. Circulation, 98, 1610-1615.
4. Cines, D.B., Rauova, L., Arepally, G., Reilly, M.P., McKenzie, S.E., Sachais, B.S. and Poncz, M. (2007): Heparin-induced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J. Clin. Apher., 22, 31-36.
5. Dunnett, C.W. (1964): New tables for multiple comparison with a control. Biomet., 16, 671-685.
6. Ginsberg, J.S. (1999): Thromboembolism and pregnancy. Thromb. Haemost., 82, 620-625.
7. Gonze, M.D., Salartash, K., Sternbergh III, W.C., Baughman, R.A., Leone-Bay, A. and Money, S.R. (2000): Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation, 101, 2658-2661.
8. Greinacher, A., Potzsch, B., Amiral, J., Dummel, V., Eichner, A. and Mueller-Eckhardt, C. (1994): Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb. Haemos., 71, 247-251.
9. Hirsh, J. and Fuster, V. (1994): Guide to anticoagulant therapy, Part 1: heparin, Circulation, 89, 14449-1468.
10. Hirsh, J. (2003): Current anticoagulant therapy-unmet clinical needs. Throm. Res., 109, S1-S8.
11. Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., McLoughlin, D. and Armstrong, P. (1979): Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N. Engl. J. Med., 301, 855-858.
12. Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G. and McLaughlin, D. (1982): Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med., 306, 189-194.
13. Hyers, T.M., Hull, R.D. and Weg, J.G. (1995): Antithrombotic therapy for venous thromboembolic disease. Chest, 108, 335S-351S.
14. Jack, H., Sonia, S.A., Jonathan, L.H. and Valentin, F. (2001): Guide to Anticoagulant Therapy: Heparin. Circulation, 103, 2994-3018.
15. Jiao, Y., Ubrich, N., Hoffart, V., Marchand-Arvier, M., Vigneron, C., Hoffman, M. and Maincent, P. (2002): Anticoagulant activity of heparin following oral administration of heparin-loaded microparticles in rabbits. J. Pharm. Sci., 91, 760-768.
16. Kim, C.-Y., Han, J.S., Suzuki, T. and Han, S.-S. (2005): Indirect indicator of transport stress in hematological values in newly acquired cynomolgus monkeys. J. Med., Primatol., 34, 188-192.
17. Kim, C.-Y., Han, S.-C., Heo, J.-D., Lee, H.-S., Ha, C.-S., Kang, B.-H., Kwon, M.-S. and Han, S.-S. (2004): Effects of transportation on hematological and serum biochemical values in cynomolgus monkeys. Kor. J. Lab. Ani. Sci., 20, 328-332.
18. Kim, C.-Y., Kim, S.K., Woo, Y.-A., Jeong, E.J., Han, S.-C., Heo, J.-D., Park, K.L. and Byun, Y.R. (2007): Toxicity screening after single dose of a newly developed oral heparin derivative in male cynomolgus monkeys. J. Toxicol. Pub. Heal., In press.
19. Kim, S.K., Vaishali, B., Lee, E., Lee, S., Lee, Y.K., Kumar, T.S., Moon, H.T. and Byun, Y. (2006): Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb. Res., 117, 419-427.
20. Lee, Y., Moon, H.T. and Byun, Y. (1998): Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res., 92, 149-156.
21. Lee, Y., Nam, J.H., Shin, H.C. and Byun, Y. (2001): Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent. Circulation, 104, 3116-3120.
22. Lee, Y.K., Kim, S.K., Lee, D.Y., Lee, S., Kim, C.-Y., Shin, H.C. and Moon, H.T. (2006): Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys. J. Control Release, 111, 290-298.
23. Malkov, D., Wang, H., Dinh, S., Steven, D. and Gomez-Orellana, I. (2002): Pathway of Oral Absorption of Heparin with Sodium N-(8-(2 Hydroxybenzoyl)Amino) Caprylate. Pharm. Res., 19, 1180-1184.
24. Mark, D.G., Jeffrey, D.M. and Andrea, L.B. (1998): Orally administered heparin for preventing deep venous thrombosis. Am. J. Surg., 176, 176-178.
25. Matsuzawa, T., Nomura, M. and Unno, T. (1993): Clinical pathology reference ranges of laboratory animals. J. Vet. Med., Sci., 55, 351-362.
26. Menajovsky, L.B. (2005): Heparin-induced thrombocytopenia: Clinical manifestations and management. Am. J. Med., 118 (Suppl. 8A), 21S-30S.
27. Shaughnessy, S.G., Young, E., Deschamps, P. and Hirsh, J. (1995): The effects of low molecular weight and standard heparin on calcium loss from the fetal rat calvaria. Blood, 86, 1368-1373.
28. Sokal, R.R. and Rohlf, F.J. (1981): Biometry, W.M. Freeman, San Francisco.
29. Strandness, D.E. Jr. (2001): Anticoagulant therapy: Current status and shortcomings. Seminars in Interventional Radiology., 18, 113-118.
30. Visentin, G.P., Ford, S.E., Scott, J.P. and Aster, R.H. (1994): Antibodies from patients with heparin induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest, 93, 81-88.
31. Welt, F.G., Woods, T.C. and Edelman, E.R. (2001): Oral heparin prevents neointimal hyperplasia after arterial injury; Inhibitory potential depends on type of vascular injury. Circulation, 104, 3121-3124.
32. Wolford, S.T., Schroer, R.A., Gohs, F.X., Gallo, P.P., Brodeck, M., Falk, H.B. and Ruhren, R.R. (1986): Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environ. Heal., 18, 161-188.